334 related articles for article (PubMed ID: 19380409)
1. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
3. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
6. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
7. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
8. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
9. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
10. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
11. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
12. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
13. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
14. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
15. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT.
Dirisamer A; Schima W; Heinisch M; Weber M; Lehner HP; Haller J; Langsteger W
Eur J Radiol; 2009 Mar; 69(3):536-41. PubMed ID: 18248928
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer therapy: the role of PET-CT in decision making.
Pons F; Duch J; Fuster D
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
[TBL] [Abstract][Full Text] [Related]
17. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
19. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
